GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Days Sales Outstanding

IRLAB Therapeutics AB (OSTO:IRLAB A) Days Sales Outstanding : 326.18 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Days Sales Outstanding?

IRLAB Therapeutics AB's average Accounts Receivable for the three months ended in Mar. 2025 was kr15.59 Mil. IRLAB Therapeutics AB's Revenue for the three months ended in Mar. 2025 was kr4.36 Mil. Hence, IRLAB Therapeutics AB's Days Sales Outstanding for the three months ended in Mar. 2025 was 326.18.

The historical rank and industry rank for IRLAB Therapeutics AB's Days Sales Outstanding or its related term are showing as below:

OSTO:IRLAB A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.85   Med: 43.44   Max: 385.28
Current: 95.84

During the past 12 years, IRLAB Therapeutics AB's highest Days Sales Outstanding was 385.28. The lowest was 7.85. And the median was 43.44.

OSTO:IRLAB A's Days Sales Outstanding is ranked worse than
66.75% of 848 companies
in the Biotechnology industry
Industry Median: 70.36 vs OSTO:IRLAB A: 95.84

IRLAB Therapeutics AB's Days Sales Outstanding increased from Mar. 2024 (0.00) to Mar. 2025 (326.18).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.


IRLAB Therapeutics AB Days Sales Outstanding Historical Data

The historical data trend for IRLAB Therapeutics AB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Days Sales Outstanding Chart

IRLAB Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 7.85 23.26 213.55 -

IRLAB Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 81.33 390.22 25.85 326.18

Competitive Comparison of IRLAB Therapeutics AB's Days Sales Outstanding

For the Biotechnology subindustry, IRLAB Therapeutics AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IRLAB Therapeutics AB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Days Sales Outstanding falls into.


;
;

IRLAB Therapeutics AB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

IRLAB Therapeutics AB's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 94.628*365
=0 / 94.628*365
=0.00

IRLAB Therapeutics AB's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

Days Sales Outstanding (Q: Mar. 2025 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Mar. 2025 )) / count ) / Revenue (A: Mar. 2025 )*Days in Period
=( (0 + 15.585) / 1 ) / 4.36*365 / 4
=15.585 / 4.36*365 / 4
=326.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IRLAB Therapeutics AB  (OSTO:IRLAB A) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


IRLAB Therapeutics AB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


IRLAB Therapeutics AB Business Description

Traded in Other Exchanges
N/A
Address
Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB Headlines

No Headlines